Somatic PIK3CA mutations as a driver of sporadic venous malformations

Science Translational Medicine

Volumn 8, Issue 332, 2016, Pages

  Castel, Pau ^a   Carmona, F Javier ^a   Grego Bessa, Joaquim ^a   Berger, Michael F ^a   Viale, Agnès ^a   Anderson, Kathryn V ^a   Bague, Silvia ^b   Scaltriti, Maurizio ^a   Antonescu, Cristina R ^a   Baselga, Eulàlia ^b   Baselga, José ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; CRE RECOMBINASE; INTEGRASE; PIK3CA PROTEIN, HUMAN; PIK3CA PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR;

ADULT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; GAIN OF FUNCTION MUTATION; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MOUSE; MOUSE MODEL; NONHUMAN; PIK3CA GENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TEK GENE; VEIN MALFORMATION; ANIMAL; DRUG EFFECTS; ENZYMOLOGY; GENETICS; MAMMALIAN EMBRYO; METABOLISM; MUTATION; PATHOLOGY; SKIN; SPINAL CORD; VASCULAR MALFORMATIONS; VASCULARIZATION;

ANIMALS; EMBRYO, MAMMALIAN; ENDOTHELIAL CELLS; INTEGRASES; MICE; MUTATION; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; SKIN; SPINAL CORD; VASCULAR MALFORMATIONS;

EID: 84962634604     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaf1164     Document Type: Article

References (70)

1. P. Brouillard, M. Vikkula, Genetic causes of vascular malformations. Hum. Mol. Gen. 16, R140-R149 (2007).
2. P. Brouillard, M. Vikkula, Vascular malformations: Localized defects in vascular morphogenesis. Clin. Genet. 63, 340-351 (2003).
3. A. Dompmartin, M. Vikkula, L. M. Boon, Venous malformation: Update on aetiopathogenesis, diagnosis and management. Phlebology 25, 224-235 (2010).
4. H.-L. Nguyen, L. M. Boon, M. Vikkula, Genetics of vascular malformations. Semin. Pediatr. Surg. 23, 221-226 (2014).
5. M. Uebelhoer, L. M. Boon, M. Vikkula, Vascular anomalies: From genetics toward models for therapeutic trials. Cold Spring Harb. Perspect. Med. 2, a009688 (2012).
6. N. Limaye, V. Wouters, M. Uebelhoer, M. Tuominen, R. Wirkkala, J. B. Mulliken, L. Eklund, L. M. Boon, M. Vikkula, Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat. Genet. 41, 118-124 (2009).
7. J. Soblet, N. Limaye, M. Uebelhoer, L. M. Boon, M. Vikkula, Variable somatic TIE2 mutations in half of sporadic venous malformations. Mol. Syndromol. 4, 179-183 (2013).
8. M. Vikkula, L. M. Boon, K. L. Carraway III, J. T. Calvert, A. J. Diamonti, B. Goumnerov, K. A. Pasyk, D. A. Marchuk, M. L. Warman, L. C. Cantley, J. B. Mulliken, B. R. Olsen, Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 87, 1181-1190 (1996).
9. C. D. Kontos, T. P. Stauffer, W.-P. Yang, J. D. York, L. Huang, M. A. Blanar, T. Meyer, K. G. Peters, Tyrosine 1101 of Tie2 is the major site of association of p85 and is required for activation of phosphatidylinositol 3-kinase and Akt. Mol. Cell. Biol. 18, 4131-4140 (1998).
10. P. N. Morris, B. J. Dunmore, A. Tadros, D. A. Marchuk, D. C. Darland, P. A. D'Amore, N. P. J. Brindle, Functional analysis of a mutant form of the receptor tyrosine kinase Tie2 causing venous malformations. J. Mol. Med. 83, 58-63 (2005).
11. E. Boscolo, N. Limaye, L. Huang, K.-T. Kang, J. Soblet, M. Uebelhoer, A. Mendola, M. Natynki, E. Seront, S. Dupont, J. Hammer, C. Legrand, C. Brugnara, L. Eklund, M. Vikkula, J. Bischoff, L. M. Boon, Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects. J. Clin. Invest. 125, 3491-3504 (2015).
12. M. Uebelhoer, M. Nätynki, J. Kangas, A. Mendola, H.-L. Nguyen, J. Soblet, C. Godfraind, L. M. Boon, L. Eklund, N. Limaye, M. Vikkula, Venous malformation-causative TIE2 mutations mediate an AKT-dependent decrease in PDGFB. Hum. Mol. Genet. 22, 3438-3448 (2013).
13. M. Nätynki, J. Kangas, I. Miinalainen, R. Sormunen, R. Pietilä, J. Soblet, L. M. Boon, M. Vikkula, N. Limaye, L. Eklund, Common and specific effects of TIE2 mutations causing venous malformations. Hum. Mol. Genet. 24, 6374-6389 (2015).
14. D. A. Fruman, C. Rommel, PI3K and cancer: Lessons, challenges and opportunities. Nat. Rev. Drug Discov. 13, 140-156 (2014).
15. J. A. Engelman, Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat. Rev. Cancer 9, 550-562 (2009).
16. K. M. Keppler-Noreuil, J. J. Rios, V. E. R. Parker, R. K. Semple, M. J. Lindhurst, J. C. Sapp, A. Alomari, M. Ezaki, W. Dobyns, L. G. Biesecker, PIK3CA-related overgrowth spectrum (PROS): Diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am. J. Med. Genet. A 167A, 287-295 (2015).
17. M. Graupera, J. Guillermet-Guibert, L. C. Foukas, L.-K. Phng, R. J. Cain, A. Salpekar, W. Pearce, S. Meek, J. Millan, P. R. Cutillas, A. J. H. Smith, A. J. Ridley, C. Ruhrberg, H. Gerhardt, B. Vanhaesebroeck, Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration. Nature 453, 662-666 (2008).
18. M. Graupera, M. Potente, Regulation of angiogenesis by PI3K signaling networks. Exp. Cell Res. 319, 1348-1355 (2013).
19. H.-C. Kang, S. T. Baek, S. Song, J. G. Gleeson, Clinical and genetic aspects of the segmental overgrowth spectrum due to somatic mutations in PIK3CA. J. Pediatr. 167, 957-962 (2015).
20. A. J. Osborn, P. Dickie, D. E. Neilson, K. Glaser, K. A. Lynch, A. Gupta, B. H. Dickie, Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations. Hum. Mol. Genet. 24, 926-938 (2015).
21. Cancer Genome Atlas Research Network, C. Kandoth, N. Schultz, A. D. Cherniack, R. Akbani, Y. Liu, H. Shen, A. G. Robertson, I. Pashtan, R. Shen, C. C. Benz, C. Yau, P. W. Laird, L. Ding, W. Zhang, G. B. Mills, R. Kucherlapati, E. R. Mardis, D. A. Levine, Integrated genomic characterization of endometrial carcinoma. Nature 497, 67-73 (2013).
22. J. R. Adams, K. Xu, J. C. Liu, N. M. R. Agamez, A. J. Loch, R. G. Wong, W. Wang, K. L. Wright, T. F. Lane, E. Zacksenhaus, S. E. Egan, Cooperation between PIK3CA and p53 mutations in mouse mammary tumor formation. Cancer Res. 71, 2706-2717 (2011).
23. C. M. Contreras, E. A. Akbay, T. D. Gallardo, J. M. Haynie, S. Sharma, O. Tagao, N. Bardeesy, M. Takahashi, J. Settleman, K. K. Wong, D. H. Castrillon, Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy. Dis. Model. Mech. 3, 181-193 (2010).
24. T. Krings, Vascular malformations of the spine and spinal cord∗: Anatomy, classification, treatment. Clin. Neuroradiol. 20, 5-24 (2010).
25. M. Wassef, F. Blei, D. Adams, A. Alomari, E. Baselga, A. Berenstein, P. Burrows, I. J. Frieden, M. C. Garzon, J. C. Lopez-Gutierrez, D. J. Lord, S. Mitchel, J. Powell, J. Prendiville, M. Vikkula; ISSVA Board and Scientific Committee, Vascular anomalies classification: Recommendations from the International Society for the Study of Vascular Anomalies. Pediatrics 136, e203-e214 (2015).
26. P. E. North, M. Waner, A. Mizeracki, M. C. Mihm Jr., GLUT1: A newly discovered immunohistochemical marker for juvenile hemangiomas. Hum. Pathol. 31, 11-22 (2000).
27. L. P. Lawley, F. Cerimele, S. W. Weiss, P. North, C. Cohen, H. P. W. Kozakewich, J. B. Mulliken, J. L. Arbiser, Expression of Wilms tumor 1 gene distinguishes vascular malformations from proliferative endothelial lesions. Arch. Dermatol. 141, 1297-1300 (2005).
28. C. Léauté-Labrèze, P. Hoeger, J. Mazereeuw-Hautier, L. Guibaud, E. Baselga, G. Posiunas, R. J. Phillips, H. Caceres, J. C. Lopez Gutierrez, R. Ballona, S. F. Friedlander, J. Powell, D. Perek, B. Metz, S. Barbarot, A. Maruani, Z. Z. Szalai, A. Krol, O. Boccara, R. Foelster-Holst, M. I. Febrer Bosch, J. Su, H. Buckova, A. Torrelo, F. Cambazard, R. Grantzow, O. Wargon, D. Wyrzykowski, J. Roessler, J. Bernabeu-Wittel, A. M. Valencia, P. Przewratil, S. Glick, E. Pope, N. Birchall, L. Benjamin, A. J. Mancini, P. Vabres, P. Souteyrand, I. J. Frieden, C. I. Berul, C. R. Mehta, S. Prey, F. Boralevi, C. C. Morgan, S. Heritier, A. Delarue, J.-J. Voisard, A randomized, controlled trial of oral propranolol in infantile hemangioma. N. Engl. J. Med. 372, 735-746 (2015).
29. P. Brouillard, L. Boon, M. Vikkula, Genetics of lymphatic anomalies. J. Clin. Invest. 124, 898-904 (2014).
30. C. Mouta-Bellum, A. Kirov, L. Miceli-Libby, M. L. Mancini, T. V. Petrova, L. Liaw, I. Prudovsky, P. E. Thorpe, N. Miura, L. C. Cantley, K. Alitalo, D. A. Fruman, C. P. H. Vary, Organ-specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from gene-targeting of the PI3K regulatory isoforms p85α, p55α, and p50α. Dev. Dyn. 238, 2670-2679 (2009).
31. S. Banerji, J. Ni, S. X. Wang, S. Clasper, J. Su, R. Tammi, M. Jones, D. G. Jackson, LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol. 144, 789-801 (1999).
32. E. C. Castro, C. Galambos, Prox-1 and VEGFR3 antibodies are superior to D2-40 in identifying endothelial cells of lymphatic malformations-A proposal of a new immunohistochemical panel to differentiate lymphatic from other vascular malformations. Pediatr. Dev. Pathol. 12, 187-194 (2009).
33. I. Arnaoutova, J. George, H. K. Kleinman, G. Benton, The endothelial cell tube formation assay on basement membrane turns 20: State of the science and the art. Angiogenesis 12, 267-274 (2009).
34. X. L. Tian, R. Kadaba, S. A. You, M. Liu, A. A. Timur, L. Yang, Q. Chen, P. Szafranski, S. Rao, L. Wu, D. E. Housman, P. E. DiCorleto, D. J. Driscoll, J. Borrow, Q. Wang, Identification of an angiogenic factor that when mutated causes susceptibility to Klippel-Trenaunay syndrome. Nature 427, 640-645 (2004).
35. C. Daly, E. Pasnikowski, E. Burova, V. Wong, T. H. Aldrich, J. Griffiths, E. Ioffe, T. J. Daly, J. P. Fandl, N. Papadopoulos, D. M. McDonald, G. Thurston, G. D. Yancopoulos, J. S. Rudge, Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells. Proc. Natl. Acad. Sci. USA. 103, 15491-15496 (2006).
36. G. Thurston, C. Daly, The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway. Cold Spring Harb. Perspect. Med. 2, a006550 (2012).
37. D. T. Cheng, T. N. Mitchell, A. Zehir, R. H. Shah, R. Benayed, A. Syed, R. Chandramohan, Z. Y. Liu, H. H. Won, S. N. Scott, A. R. Brannon, C. O'Reilly, J. Sadowska, J. Casanova, A. Yannes, J. F. Hechtman, J. Yao, W. Song, D. S. Ross, A. Oultache, S. Dogan, L. Borsu, M. Hameed, K. Nafa, M. E. Arcila, M. Ladanyi, M. F. Berger, Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17, 251-264 (2015).
38. Y. Samuels, L. A. Diaz Jr., O. Schmidt-Kittler, J. M. Cummins, L. Delong, I. Cheong, C. Rago, D. L. Huso, C. Lengauer, K. W. Kinzler, B. Vogelstein, V. E. Velculescu, Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7, 561-573 (2005).
39. N. Jones, Z. Master, J. Jones, D. Bouchard, Y. Gunji, H. Sasaki, R. Daly, K. Alitalo, D. J. Dumont, Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. J. Biol. Chem. 274, 30896-30905 (1999).
40. S. Hayashi, A. P. McMahon, Efficient recombination in diverse tissues by a tamoxifeninducible form of Cre: A tool for temporally regulated gene activation/inactivation in the mouse. Dev. Biol. 244, 305-318 (2002).
41. Y. Ruzankina, C. Pinzon-Guzman, A. Asare, T. Ong, L. Pontano, G. Cotsarelis, V. P. Zediak, M. Velez, A. Bhandoola, E. J. Brown, Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss. Cell Stem Cell 1, 113-126 (2007).
42. R. H. Adams, K. Alitalo, Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell Biol. 8, 464-478 (2007).
43. M. C. Smith, D. Y. Li, K. J. Whitehead, Mechanisms of vascular stability and the relationship to human disease. Curr. Opin. Hematol. 17, 237-244 (2010).
44. S. P. Herbert, D. Y. R. Stainier, Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat. Rev. Mol. Cell Biol. 12, 551-564 (2011).
45. S. D. Castillo, E. Tzouanacou, M. Zaw-Thin, I. M. Berenjeno, V. Parker, I. Chivite, M. Milà-Guasch, W. Pearce, I. Solomon, A. Angulo-Urarte, A. M. Figueiredo, R. E. Dewhurst, R. G. Knox, G. R. Clark, C. L. Scudamore, A. Badar, T. L. Kalber, J. Foster, D. J. Stuckey, A. L. David, W. A. Phillips, M. F. Lythgoe, V. Wilson, R. K. Semple, N. J. Sebire, V. A. Kinsler, M. Graupera, B. Vanhaesebroeck, Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans. Sci. Transl. Med. 8, 332ra43 (2016).
46. A. Dompmartin, F. Ballieux, P. Thibon, A. Lequerrec, C. Hermans, P. Clapuyt, M.-T. Barrellier, F. Hammer, D. Labbé, M. Vikkula, L. M. Boon, Elevated D-dimer level in the differential diagnosis of venous malformations. Arch. Dermatol. 145, 1239-1244 (2009).
47. C. Fritsch, A. Huang, C. Chatenay-Rivauday, C. Schnell, A. Reddy, M. Liu, A. Kauffmann, D. Guthy, D. Erdmann, A. De Pover, P. Furet, H. Gao, S. Ferretti, Y. Wang, J. Trappe, S. M. Brachmann, S.-M. Maira, C. Wilson, M. Boehm, C. Garcia-Echeverria, P. Chene, M. Wiesmann, R. Cozens, J. Lehar, R. Schlegel, G. Caravatti, F. Hofmann, W. R. Sellers, Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol. Cancer Ther. 13, 1117-1129 (2014).
48. H. Lackner, A. Karastaneva, W. Schwinger, M. Benesch, P. Sovinz, M. Seidel, D. Sperl, S. Lanz, E. Haxhija, F. Reiterer, E. Sorantin, C. E. Urban, Sirolimus for the treatment of children with various complicated vascular anomalies. Eur. J. Pediatr. 174, 1579-1584 (2015).
49. A. M. Hammill, M. Wentzel, A. Gupta, S. Nelson, A. Lucky, R. Elluru, R. Dasgupta, R. G. Azizkhan, D. M. Adams, Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr. Blood Cancer 57, 1018-1024 (2011).
50. J. Rodon, R. Dienstmann, V. Serra, J. Tabernero, Development of PI3K inhibitors: Lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. 10, 143-153 (2013).
51. L. M. Hare, Q. Schwarz, S. Wiszniak, R. Gurung, K. G. Montgomery, C. A. Mitchell, W. A. Phillips, Heterozygous expression of the oncogenic PIK3CA (H1047R) mutation during murine development results in fatal embryonic and extraembryonic defects. Dev. Biol. 404, 14-26 (2015).
52. Y. Y. Kisanuki, R. E. Hammer, J.-I. Miyazaki, S. C. Williams, J. A. Richardson, M. Yanagisawa, Tie2-Cre transgenic mice: A new model for endothelial cell-lineage analysis in vivo. Dev. Biol. 230, 230-242 (2001).
53. J. A. Cox, E. Bartlett, E. I. Lee, Vascular Malformations: A review. Semin. Plast. Surg. 28, 58-63 (2014).
54. A. A. De Lorimier, Sclerotherapy for venous malformations. J. Pediatr. Surg. 30, 188-194 (1995).
55. J. Heyer, L. N. Kwong, S. W. Lowe, L. Chin, Non-germline genetically engineered mouse models for translational cancer research. Nat. Rev. Cancer 10, 470-480 (2010).
56. M. H. Van Miltenburg, J. Jonkers, Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches. Curr. Opin. Genet. Dev. 22, 21-27 (2012).
57. J. T. Calvert, T. J. Riney, C. D. Kontos, E. H. Cha, V. G. Prieto, C. R. Shea, J. N. Berg, N. C. Nevin, S. A. Simpson, K. A. Pasyk, M. C. Speer, K. G. Peters, D. A. Marchuk, Allelic and locus heterogeneity in inherited venous malformations. Hum. Mol. Genet. 8, 1279-1289 (1999).
58. V. Wouters, N. Limaye, M. Uebelhoer, A. Irrthum, L. M. Boon, J. B. Mulliken, O. Enjolras, E. Baselga, J. Berg, A. Dompmartin, S. A. Ivarsson, L. Kangesu, Y. Lacassie, J. Murphy, A. S. Teebi, A. Penington, P. Rieu, M. Vikkula, Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects. Eur. J. Hum. Genet. 18, 414-420 (2010).
59. I. Kim, H. G. Kim, J.-N. So, J. H. Kim, H. J. Kwak, G. Y. Koh, Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Circ. Res. 86, 24-29 (2000).
60. K. C. Kurek, V. L. Luks, U. M. Ayturk, A. I. Alomari, S. J. Fishman, S. A. Spencer, J. B. Mulliken, M. E. Bowen, G. L. Yamamoto, H. P. Kozakewich, M. L. Warman, Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am. J. Hum. Genet. 90, 1108-1115 (2012).
61. V. L. Luks, N. Kamitaki, M. P. Vivero, W. Uller, R. Rab, J. V. M. G. Bovée, K. L. Rialon, C. J. Guevara, A. I. Alomari, A. K. Greene, S. J. Fishman, H. P. W. Kozakewich, R. A. Maclellan, J. B. Mulliken, R. Rahbar, S. A. Spencer, C. C. Trenor III, J. Upton, D. Zurakowski, J. A. Perkins, A. Kirsh, J. T. Bennett, W. B. Dobyns, K. C. Kurek, M. L. Warman, S. A. McCarroll, R. Murillo, Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. J. Pediatr. 166, 1048-1054 (2015).
62. M. J. Lindhurst, V. E. R. Parker, F. Payne, J. C. Sapp, S. Rudge, J. Harris, A. M. Witkowski, Q. Zhang, M. P. Groeneveld, C. E. Scott, A. Daly, S. M. Huson, L. L. Tosi, M. L. Cunningham, T. N. Darling, J. Geer, Z. Gucev, V. R. Sutton, C. Tziotzios, A. K. Dixon, T. Helliwell, S. O'Rahilly, D. B. Savage, M. J. O. Wakelam, I. Barroso, L. G. Biesecker, R. K. Semple, Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat. Genet. 44, 928-933 (2012).
63. M. J. Lindhurst, J. C. Sapp, J. K. Teer, J. J. Johnston, E. M. Finn, K. Peters, J. Turner, J. L. Cannons, D. Bick, L. Blakemore, C. Blumhorst, K. Brockmann, P. Calder, N. Cherman, M. A. Deardorff, D. B. Everman, G. Golas, R. M. Greenstein, B. M. Kato, K. M. Keppler-Noreuil, S. A. Kuznetsov, R. T. Miyamoto, K. Newman, D. Ng, K. O'Brien, S. Rothenberg, D. J. Schwartzentruber, V. Singhal, R. Tirabosco, J. Upton, S. Wientroub, E. H. Zackai, K. Hoag, T. Whitewood-Neal, P. G. Robey, P. L. Schwartzberg, T. N. Darling, L. L. Tosi, J. C. Mullikin, L. G. Biesecker, A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N. Engl. J. Med. 365, 611-619 (2011).
64. J.-B. Rivière, G. M. Mirzaa, B. J. O'Roak, M. Beddaoui, D. Alcantara, R. L. Conway, J. St-Onge, J. A. Schwartzentruber, K. W. Gripp, S. M. Nikkel, T. Worthylake, C. T. Sullivan, T. R. Ward, H. E. Butler, N. A. Kramer, B. Albrecht, C. M. Armour, L. Armstrong, O. Caluseriu, C. Cytrynbaum, B. A. Drolet, A. M. Innes, J. L. Lauzon, A. E. Lin, G. M. S. Mancini, W. S. Meschino, J. D. Reggin, A. K. Saggar, T. Lerman-Sagie, G. Uyanik, R. Weksberg, B. Zirn, C. L. Beaulieu; Finding of Rare Disease Genes (FORGE) Canada Consortium, J. Majewski, D. E. Bulman, M. O'Driscoll, J. Shendure, J. M. Graham Jr., K. M. Boycott, W. B. Dobyns, De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat. Genet. 44, 934-940 (2012).
65. M. D. Shirley, H. Tang, C. J. Gallione, J. D. Baugher, L. P. Frelin, B. Cohen, P. E. North, D. A. Marchuk, A. M. Comi, J. Pevsner, Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N. Engl. J. Med. 368, 1971-1979 (2013).
66. D. J. Marsh, P. L. M. Dahia, Z. Zheng, D. Liaw, R. Parsons, R. J. Gorlin, C. Eng, Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat. Genet. 16, 333-334 (1997).
67. A. Roy, J. Ni, J. Skibo, S. Rankin, W. B. Dobyns, F. Kalume, S. J. Baker, J. Zhao, K. J. Millen, Modeling human PIK3CA-related congenital brain overgrowth and epilepsy in mice. Int. J. Dev. Neurosci. 47, 46 (2015).
68. C. Pföhler, E. Janssen, A. Buecker, T. Vogt, C. S. L. Müller, Successful treatment of a congenital extra-truncal vascular malformation by orally administered propranolol. J. Dermatol. Treat. 26, 59-62 (2015).
69. J. Blatt, T. W. McLean, S. M. Castellino, C. N. Burkhart, A review of contemporary options for medical management of hemangiomas, other vascular tumors, and vascular malformations. Pharmacol. Ther. 139, 327-333 (2013).
70. D. D. Sarbassov, S. M. Ali, S. Sengupta, J.-H. Sheen, P. P. Hsu, A. F. Bagley, A. L. Markhard, D. M. Sabatini, Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159-168 (2006).